Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 21:54 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 4,126 | $232.51 | $959,336.26 |
DisclosureSEC source: 0000899243-22-007205 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,312 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,439 | $232.51 | $799,601.89 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,999 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:55 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 3,439 | $232.51 | $799,601.89 |
DisclosureSEC source: 0000899243-22-007206 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,065 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:56 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 8,584 | $232.51 | $1,995,865.84 |
DisclosureSEC source: 0000899243-22-007208 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,088 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:57 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 8,236 | $232.51 | $1,914,952.36 |
DisclosureSEC source: 0000899243-22-007209 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,090 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:59 UTC |
Liu JoySVP, General Counsel
|
Tax withholdingCommon Stock | 712 | $232.51 | $165,547.12 |
DisclosureSEC source: 0000899243-22-007213 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,008 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:01 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 3,497 | $232.51 | $813,087.47 |
DisclosureSEC source: 0000899243-22-007214 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,578 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:02 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 3,439 | $232.51 | $799,601.89 |
DisclosureSEC source: 0000899243-22-007215 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:04 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 3,439 | $232.51 | $799,601.89 |
DisclosureSEC source: 0000899243-22-007217 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,562 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:03 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 4,114 | $232.51 | $956,546.14 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,623 Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:05 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,444 | $232.02 | $567,056.88 |
DisclosureSEC source: 0001209191-22-010175 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,438 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $232.02 (range $231.82 to $232.60). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 98 | $237.23 | $23,248.54 |
DisclosureSEC source: 0001209191-22-009232 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,882 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 601 | $236.28 | $142,004.28 |
DisclosureSEC source: 0001209191-22-009232 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,980 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $236.28 (range $235.84 to $236.74). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 757 | $234.95 | $177,857.15 |
DisclosureSEC source: 0001209191-22-009232 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,581 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $234.95 (range $234.47 to $235.28). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 841 | $233.92 | $196,726.72 |
DisclosureSEC source: 0001209191-22-009232 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,338 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.36 to $234.30). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 42 | $236.85 | $9,947.70 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,737 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.84 to $236.87). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 70 | $235.87 | $16,510.90 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,779 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $235.87 (range $235.41 to $236.08). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 78 | $234.93 | $18,324.54 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,849 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $234.93 (range $234.28 to $235.25). Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:22 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 100 | $233.92 | $23,392.00 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,927 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $233.92 (range $233.26 to $234.24). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:13 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 3,040 | $237.74 | $722,729.60 |
DisclosureSEC source: 0001209191-22-009233 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,438 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,518 | $237.74 | $836,369.32 |
DisclosureSEC source: 0001209191-22-009232 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,179 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:14 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 2,437 | $237.74 | $579,372.38 |
DisclosureSEC source: 0001209191-22-009234 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,504 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:16 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 3,031 | $237.74 | $720,589.94 |
DisclosureSEC source: 0001209191-22-009236 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,672 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:18 UTC |
Liu JoySVP, General Counsel
|
Tax withholdingCommon Stock | 474 | $237.74 | $112,688.76 |
DisclosureSEC source: 0001209191-22-009238 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,720 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 2,491 | $237.74 | $592,210.34 |
DisclosureSEC source: 0001209191-22-009242 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,075 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:21 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 979 | $237.74 | $232,747.46 |
DisclosureSEC source: 0001209191-22-009245 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,973 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:22 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 1,230 | $237.74 | $292,420.20 |
DisclosureSEC source: 0001209191-22-009249 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,027 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:24 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 2,434 | $237.74 | $578,659.16 |
DisclosureSEC source: 0001209191-22-009252 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,001 Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,660 | $86.52 Strike: $86.52 | $403,183.20 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · derivative · entry 12 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Fully vested. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 300 | $254.46 | $76,338.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 11 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,697 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,099 | $253.41 | $278,497.59 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 10 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,997 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 900 | $252.10 | $226,890.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 9 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,096 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 980 | $251.22 | $246,195.60 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,996 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 754 | $249.97 | $188,477.38 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,976 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 127 | $248.65 | $31,578.55 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,730 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 500 | $247.73 | $123,865.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,857 F4 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34). F6 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 4,660 | $86.52 | $403,183.20 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 6,279 | $243.63 | $1,529,752.77 |
DisclosureSEC source: 0001209191-22-006779 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,326 Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 16 | $254.54 | $4,072.64 |
DisclosureSEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 8 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,952 F3 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F5 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 64 | $253.95 | $16,252.80 |
DisclosureSEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 7 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,968 F3 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F5 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 149 | $253.07 | $37,707.43 |
DisclosureSEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 6 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,032 F3 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F5 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 141 | $251.47 | $35,457.27 |
DisclosureSEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 5 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,181 F3 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F5 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85). Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 670 | $250.04 | $167,526.80 |
DisclosureSEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 4 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,322 F3 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97). F5 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:29 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 2,944 | $250.07 | $736,206.08 |
DisclosureSEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,435 F4 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $250.07 (range $250.00 to $250.09). F6 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 12,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,697 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 11,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,383 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:06 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 8,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006757 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,755 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:09 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
GrantCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006761 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:12 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 14,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006767 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,478 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:12 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 13,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006767 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,855 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.